Other: — Drugs: — Other
Part of: 293590 — Other:
N360727 · 2026-05-12 — The tariff classification of Tenapanor Hydrochloride (CAS No. 1234365-97-9) in bulk form, from Taiwan
, Ltd.Tenapanor Hydrochloride is a sodium/hydrogen exchanger 3 (NHE3) inhibitor. It is indicated for thetreatment of adults with irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in adultswith chronic kidney disease.The applicable subheading for the Tenapanor Hydrochloride in bulk form will be 2935.90.6000, HarmonizedTariff Schedule of the United States (HTSUS), which provides for “Sulfonamides: Other: Other: Drugs:Other.” The general rate of duty will be 6.5 percent ad valorem. Currently, Tenapanor Hydrochloride is notlisted in the Pharmaceutical Appendix to the Tariff…
N302448 · 2019-02-05 — The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk powder form, from Taiwan
Baricitinib is a Janus kinase inhibitor which functions by inhibiting the activity of selective JAK1 and JAK2 enzymes. It is indicated for the treatment of rheumatoid arthritis. The applicable subheading for the Baricitinib in bulk form will be 2935.90.6000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Sulfonamides: Other: Other: Drugs: Other.” The rate of duty will be 6.5 percent ad valorem. Currently, Baricitinib is not listed in the Pharmaceutical Appendix to the Tariff Schedule. Duty rates are provided for your convenience and are subject to change. The…
N299228 · 2018-08-14 — The tariff classification of Sparsentan (CAS No. 254740-64-2) in bulk powder form, from China
, you requested a tariff classification ruling. Sparsentan, is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed by Retrophin, Inc. for the treatment of focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease. In your letter, you state that Retrophin, Inc. has successfully concluded Phase II trials of Sparsentan and anticipates Phase III trials will be commenced shortly. The applicable subheading for the Sparsentan in bulk powder form will be 2935.90.6000, Harmonized Tariff Schedule of the…
N289587 · 2017-09-18 — The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk powder form, from Taiwan
Baricitinib is a Janus kinase inhibitor, which functions by inhibiting the activity of selective JAK1 and JAK2 enzymes. Currently, Baricitinib is an investigational drug that is undergoing phase III clinical trials for the treatment of rheumatoid arthritis. The applicable subheading for the Baricitinib in bulk form will be 2935.90.6000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Sulfonamides: Other: Other: Drugs: Other.” The rate of duty will be 6.5 percent ad valorem. Currently, Baricitinib is not listed in the Pharmaceutical Appendix to the Tariff Schedule.…
N285338 · 2017-05-03 — The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk form, from Taiwan
, you requested a tariff classification ruling. Baricitinib is a Janus kinase inhibitor, which functions by inhibiting the activity of selective JAK1 and JAK2 enzymes. Currently, Baricitinib, is an investigational drug that is undergoing phase III clinical trials for the treatment of rheumatoid arthritis. The applicable subheading for the Baricitinib in bulk form will be 2935.90.6000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Sulfonamides: Other: Other: Drugs: Other.” The rate of duty will be 6.5 percent ad valorem. Currently, Baricitinib is not listed in…
Not sure this code fits your product? HaiLang AI determines the US HTS code from a description in about a minute.
Classify a product